In this episode, VTE rate with abemaciclib (uh-bem-uh-cy-clib) higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant (ee-las-cess-trant) for metastatic disease; and more.
Read the full coverage here:
VTE rate with abemaciclib higher in real-world setting among patients with breast cancer
Enhertu extends progression-free survival in breast cancer subgroup, topline data show
FDA grants priority review to elacestrant for metastatic breast cancer
Lack of financial comfort linked to weight gain among young breast cancer survivors
Hispanic ethnicity often not reported in breast cancer studies
References:
Bazan JG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.3527.
